| (Values in U.S. Thousands) | Sep, 2025 | Jun, 2025 | Mar, 2025 | Dec, 2024 | Sep, 2024 |
| Sales | 140 | 320 | 380 | 600 | 770 |
| Sales Growth | -56.25% | -15.79% | -36.67% | -22.08% | +63.83% |
| Net Income | -7,220 | -5,030 | -5,010 | -4,080 | -4,420 |
| Net Income Growth | -43.54% | -0.40% | -22.79% | +7.69% | -29.62% |
Longeveron Inc (LGVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Longeveron Inc. is a clinical stage biotechnology company. It engages in developing cellular therapies for chronic aging-related and life-threatening conditions. The company's investigational product includes LOMECEL-B(TM). Longeveron Inc. is based in MIAMI.
Fiscal Year End Date: 12/31